F
Fiona C Brownfoot
Researcher at Mercy Hospital for Women
Publications - 83
Citations - 1680
Fiona C Brownfoot is an academic researcher from Mercy Hospital for Women. The author has contributed to research in topics: Preeclampsia & Endothelial dysfunction. The author has an hindex of 18, co-authored 66 publications receiving 1177 citations. Previous affiliations of Fiona C Brownfoot include Tokyo University of Pharmacy and Life Sciences & Royal Women's Hospital.
Papers
More filters
Journal ArticleDOI
Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth
TL;DR: It remains unclear whether one corticosteroid (or one particular regimen) has advantages over another, and the suggestion that 12-hour dosing may be as effective as 24- hour dosing of betamethasone based on one small trial is suggested.
Journal ArticleDOI
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction
Fiona C Brownfoot,Roxanne Hastie,Natalie J. Hannan,Ping Cannon,Laura Tuohey,Laura J. Parry,Sevvandi Senadheera,Sebastian E. Illanes,Tu'uhevaha J Kaitu'u-Lino,Stephen Tong +9 more
TL;DR: The effects of metformin on endothelial dysfunction, maternal blood vessel vasodilation, and angiogenesis are examined and it is suggested that soluble fms-like tyrosine kinase 1 and soluble endoglin secretion is regulated through the mitochondria.
Journal ArticleDOI
Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia
Fiona C Brownfoot,Stephen Tong,Natalie J. Hannan,Natalie K Binder,Susan P. Walker,Ping Cannon,Roxanne Hastie,Kenji Onda,Tu'uhevaha J Kaitu'u-Lino +8 more
TL;DR: Results indicate that pravastatin reduced sFlt-1 and soluble endoglin production and decreased endothelial dysfunction in primary human tissues, and pilot data is presented, suggesting that prabastatin can stabilize clinical and biochemical features of preterm preeclampsia.
Journal ArticleDOI
Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction
Kenji Onda,Kenji Onda,Stephen Tong,Sally Beard,Natalie K Binder,Masanaga Muto,Sevvandi Senadheera,Laura J. Parry,Laura J. Parry,Mark Dilworth,Lewis Renshall,Lewis Renshall,Fiona C Brownfoot,Roxanne Hastie,Laura Tuohey,Kirsten R Palmer,Toshihiko Hirano,Masahito Ikawa,Tu'uhevaha J Kaitu'u-Lino,Natalie J. Hannan +19 more
TL;DR: Functional studies on primary human tissues and animal models have found that proton pump inhibitors decrease sFlt-1 and soluble endoglin secretion and endothelial dysfunction, dilate blood vessels, decrease blood pressure, and have antioxidant and anti-inflammatory properties.
Journal ArticleDOI
Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin.
Tu'uhevaha J Kaitu'u-Lino,Stephen Tong,Sally Beard,Roxanne Hastie,Laura Tuohey,Fiona C Brownfoot,Kenji Onda,Natalie J. Hannan +7 more
TL;DR: A protocol is presented that yields primary trophoblasts of high purity that produce abundant sFlt-1 and low but detectable levels of sEng, which are readily amenable to gene silencing by siRNAs and hence suitable for functional studies.